Abstract
Surfactant replacement therapy for the treatment of respiratory distress syndrome (RDS) and other respiratory diseases in newborns has become one of the most active research areas in neonatology. This research has resulted in improved survival for preterm babies since becoming a routine treatment in the 1990s. The main characteristics of pulmonary surfactant, including its composition, pool, metabolism, inactivation and immediate effects after administration, are well-established. However, some doubts still remain about the use of exogenous surfactants and must be addressed. The new generation of synthetic surfactants has raised questions regarding the choice of surfactant type, the ideal timing for treatment (prophylactic vs early rescue strategy), the adequate dose and number of doses, new administration routes and the effects of the association between the use of antenatal steroids and the surfactant replacement therapy. There is also controversy surrounding the choice between early surfactant administration and the use of a nasal CPAP as an initial strategy to treat RDS and to reduce bronchopulmonary dysplasia (BPD). This article reviews basic and clinical aspects of surfactant replacement therapy for RDS and other respiratory diseases in newborns.
Keywords: Surfactant, respiratory distress syndrome, antenatal steroids, mechanical ventilation, newborn, respiratory insufficiency, bronchopulmonary dysplasia, Alveolar edema, atelectasis/hyperdistention, alveolar expansion
Current Respiratory Medicine Reviews
Title: Multiple Utilization of Surfactant in Neonatology
Volume: 8 Issue: 1
Author(s): Celso Moura Rebello
Affiliation:
Keywords: Surfactant, respiratory distress syndrome, antenatal steroids, mechanical ventilation, newborn, respiratory insufficiency, bronchopulmonary dysplasia, Alveolar edema, atelectasis/hyperdistention, alveolar expansion
Abstract: Surfactant replacement therapy for the treatment of respiratory distress syndrome (RDS) and other respiratory diseases in newborns has become one of the most active research areas in neonatology. This research has resulted in improved survival for preterm babies since becoming a routine treatment in the 1990s. The main characteristics of pulmonary surfactant, including its composition, pool, metabolism, inactivation and immediate effects after administration, are well-established. However, some doubts still remain about the use of exogenous surfactants and must be addressed. The new generation of synthetic surfactants has raised questions regarding the choice of surfactant type, the ideal timing for treatment (prophylactic vs early rescue strategy), the adequate dose and number of doses, new administration routes and the effects of the association between the use of antenatal steroids and the surfactant replacement therapy. There is also controversy surrounding the choice between early surfactant administration and the use of a nasal CPAP as an initial strategy to treat RDS and to reduce bronchopulmonary dysplasia (BPD). This article reviews basic and clinical aspects of surfactant replacement therapy for RDS and other respiratory diseases in newborns.
Export Options
About this article
Cite this article as:
Moura Rebello Celso, Multiple Utilization of Surfactant in Neonatology, Current Respiratory Medicine Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339812798868924
DOI https://dx.doi.org/10.2174/157339812798868924 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Abiotic Regulation: A Common Way for Proteins to Modulate their Functions
Current Protein & Peptide Science Neural Induction and Patterning in Mammalian Pluripotent Stem Cells
CNS & Neurological Disorders - Drug Targets Dietary Interventions in Children with Autism Spectrum Disorders - An Updated Review of the Research Evidence
Current Clinical Pharmacology Impact of Alzheimers Disease on the Functional Connectivity of Spontaneous Brain Activity
Current Alzheimer Research Systemic and Biophase Bioavailability and Pharmacokinetics of Nanoparticulate Drug Delivery Systems
Current Drug Delivery Gait-Related Strategies for the Prevention of Plantar Ulcer Development in the High Risk Foot
Current Diabetes Reviews Wound Healing Agents: The Role of Natural and Non-Natural Products in Drug Development
Mini-Reviews in Medicinal Chemistry Inhibitors of Catechol-O-methyltransferase in the Treatment of Neurological Disorders
Central Nervous System Agents in Medicinal Chemistry The Impact of Dementia Development Concurrent with Parkinson's Disease: A New Perspective
CNS & Neurological Disorders - Drug Targets Patterns of Gray and White Matter Changes in Individuals at Risk for Alzheimer’s Disease
Current Alzheimer Research Analysing and Understanding the Singing Voice: Recent Progress and Open Questions
Current Bioinformatics Review on Hydrate Dissociation Kinetic Behavior
Current Physical Chemistry Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Recent Advances, Issues and Patents on Medical Nanorobots
Recent Patents on Engineering Freezing of Gait in Parkinsonism and its Potential Drug Treatment
Current Neuropharmacology Gum-Chewing and Headache: An Underestimated Trigger of Headache Pain in Migraineurs?
CNS & Neurological Disorders - Drug Targets Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
Current Drug Targets Introduction to Psychiatric/Psychosocial Rehabilitation (PSR): History and Foundations
Current Psychiatry Reviews Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Current Drug Targets